Management of Castration Resistant Prostate Cancer 2014
Published on 15. September 2015
Book
Paperback/Softback
337 pages
978-1-4939-2869-9 (ISBN)
Description
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.
Reviews / Votes
From the book reviews: "This volume in the Current Clinical Urology series focuses on the management of castration resistant prostate cancer (CRPC), providing an important reference for medical oncologists, urologists, and radiation oncologists. The authors successfully update the biology and clinical aspects of CRPC management. ... This book sets out the most current knowledge about the management of CRPC, a fascinating area in clinical urology. It should be part of the library of any clinician or basic scientist dealing with prostate cancer." (Jianqing Lin, Doody's Book Reviews, November, 2014)More details
Series
Edition
2014 ed.
Language
English
Place of publication
Totowa, NJ
United States
Target group
Professional and scholarly
Professional/practitioner
Illustrations
35 s/w Tabellen
35 black & white tables, biography
Dimensions
Height: 254 mm
Width: 178 mm
ISBN-13
978-1-4939-2869-9 (9781493928699)
DOI
10.1007/978-1-4939-1176-9
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Fred Saad | Mario A. Eisenberger
Management of Castration Resistant Prostate Cancer
Book
08/2014
Humana Press Inc.
€160.49
Shipment within 15-20 days
Persons
Fred Saad, MD, FRCS Professor and Chief of Urology, Director of GU Oncology, University of Montreal Endowed Chair in Prostate Cancer, University of Montreal Hospital Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada. Mario A. Eisenberger, MD R. Dale Hughes Professor of Oncology and Urology, The Johns Hopkins University, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Content
Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations Chapter 1 - Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities - Mario A. Eisenberger and Fred Saad Chapter 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm - Tian Zhang and Andrew J. Armstrong Chapter 3. Molecular Mechanisms of Prostate Cancer Progression after Castration - William G. Nelson and Kenneth J. Pienta Chapter 4. New Imaging Modalities - Steve Y. Cho, Seyed S. Dianat and Katarzyna Macura Part II. TREATMENT - The Androgen Receptor Signaling Axis biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals Chapter 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer - Heather H. Cheng and Bruce Montgomery Chapter 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer - Jarett L. Feldman, Dana Rathkopf and Michael J. Morris Chapter 7. Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) - Adam Siegel and Charles J. Ryan Chapter 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) - Robert J. van Soest, Ellen S. de Morree, Cora N. Sternberg and Ronald de Wit Chapter 9. The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer - Romulado Barroso-Sousa and Charles G. Drake Chapter 10. Bone Targeted Therapy: Rationale and Current Status - Benjamin A. Gartrell and Fred Saad Chapter 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer - Oliver Sartor and Brian Lewis Part III. New Drug Development: Clinical Trials Design in CRPC Chapter 12. Introduction - Aurelius Omlin, Carmel Pezaro and Johann S. de Bono Chapter 13. Phase I/II targeted treatments - Aurelius Omlin, Carmel Pezaro and Johann S. de Bono Chapter 14. Defining Clinical Endpoints in Castration-resistant Prostate Cancer - Jorge A. Garcia and Robert Dreicer Part IV. New Drug Development: Specific Targets Chapter 15. Angiogenesis Inhibition in Castration Resistant Prostate Cancer - Daniel J. George, William Kelly and Aaron Mitchell Chapter 16. Co-targeting Adaptive Survival Pathways - Amina Zoubeidi and Martin Gleave Chapter 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer - Hans J. Hammers and Emmanuel S. Antonarakis Chapter 18. PARP Inhibitors - Joaquin Mateo, Timothy A. Yap and Johann S. De Bono Chapter 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer - Petros D. Grivas and David C. Smith Chapter 20. Epigenetics in Castration Resistant Prostate Cancer - Leigh Ellis, Sheng-Yu Ku, Elena Lasorsa and Roberto Pili Chapter 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype - Himisha Beltran, Gurveen Kaur, Myriam Kossai, David M. Nanus and Scott T. Tagawa Part V. Clinical Management Aspects Chapter 22. Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management - Channing J. Paller and Thomas J. Smith Chapter 23. Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development - Jacob A. Martin and William K. Oh